Cargando…

Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India

OBJECTIVES: As per National AIDS Control Organization (NACO) estimates, there are 2.1 million people living with HIV (PWH) in India, of whom 1.2 million are on first‐line antiretroviral therapy (ART). This study explored the use of a single‐tablet regimen containing tenofovir disoproxil fumarate 300...

Descripción completa

Detalles Bibliográficos
Autores principales: Dravid, A, Betha, TP, Sharma, AK, Gawali, R, Mahajan, U, Kulkarni, M, Saraf, C, Kore, S, Dravid, M, Rathod, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539943/
https://www.ncbi.nlm.nih.gov/pubmed/33021066
http://dx.doi.org/10.1111/hiv.12912
_version_ 1783591118718369792
author Dravid, A
Betha, TP
Sharma, AK
Gawali, R
Mahajan, U
Kulkarni, M
Saraf, C
Kore, S
Dravid, M
Rathod, N
author_facet Dravid, A
Betha, TP
Sharma, AK
Gawali, R
Mahajan, U
Kulkarni, M
Saraf, C
Kore, S
Dravid, M
Rathod, N
author_sort Dravid, A
collection PubMed
description OBJECTIVES: As per National AIDS Control Organization (NACO) estimates, there are 2.1 million people living with HIV (PWH) in India, of whom 1.2 million are on first‐line antiretroviral therapy (ART). This study explored the use of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg + efavirenz 400 mg (TLE400 STR) as a first‐line switch strategy in PWH in Pune, India. METHODS: This retrospective cohort study was conducted in private sector ART clinics in three tertiary‐level hospitals in Pune, India. PWH > 12 years of age (n = 502) who initiated first‐line ART (predominantly TLE600 STR), completed ≥ 6 months of follow‐up and achieved virological suppression [plasma viral load (VL) < 1000 HIV‐1 RNA copies/mL] were identified and switched to TLE400 STR. The virological and immunological efficacy of TLE400 STR at 6 and 12 months of follow‐up were noted. Grade 3/4 adverse events (especially efavirenz‐related neuropsychiatric adverse events) leading to regimen discontinuation were also noted. RESULTS: Of 502 PWH who switched to TLE400 STR, complete virological suppression (VL < 20 copies/mL) was maintained in more than 97% of patients at follow‐up. TLE400 STR was successful in maintaining CD4 counts within the range observed at the start of the regimen. Grade 3/4 adverse events leading to TLE400 STR discontinuation were seen in 11 (2.2%) patients. Virological failure (VL > 1000 copies/mL) and treatment regimen failure were seen in six (1.2%) and 49 (9.8%) subjects, respectively. CONCLUSIONS: TLE400 STR exhibits excellent efficacy and safety as a switch strategy and should be introduced in the Indian National ART Program, especially for PWH who are virologically suppressed on TLE600 STR.
format Online
Article
Text
id pubmed-7539943
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75399432020-10-09 Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India Dravid, A Betha, TP Sharma, AK Gawali, R Mahajan, U Kulkarni, M Saraf, C Kore, S Dravid, M Rathod, N HIV Med Original Research OBJECTIVES: As per National AIDS Control Organization (NACO) estimates, there are 2.1 million people living with HIV (PWH) in India, of whom 1.2 million are on first‐line antiretroviral therapy (ART). This study explored the use of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg + efavirenz 400 mg (TLE400 STR) as a first‐line switch strategy in PWH in Pune, India. METHODS: This retrospective cohort study was conducted in private sector ART clinics in three tertiary‐level hospitals in Pune, India. PWH > 12 years of age (n = 502) who initiated first‐line ART (predominantly TLE600 STR), completed ≥ 6 months of follow‐up and achieved virological suppression [plasma viral load (VL) < 1000 HIV‐1 RNA copies/mL] were identified and switched to TLE400 STR. The virological and immunological efficacy of TLE400 STR at 6 and 12 months of follow‐up were noted. Grade 3/4 adverse events (especially efavirenz‐related neuropsychiatric adverse events) leading to regimen discontinuation were also noted. RESULTS: Of 502 PWH who switched to TLE400 STR, complete virological suppression (VL < 20 copies/mL) was maintained in more than 97% of patients at follow‐up. TLE400 STR was successful in maintaining CD4 counts within the range observed at the start of the regimen. Grade 3/4 adverse events leading to TLE400 STR discontinuation were seen in 11 (2.2%) patients. Virological failure (VL > 1000 copies/mL) and treatment regimen failure were seen in six (1.2%) and 49 (9.8%) subjects, respectively. CONCLUSIONS: TLE400 STR exhibits excellent efficacy and safety as a switch strategy and should be introduced in the Indian National ART Program, especially for PWH who are virologically suppressed on TLE600 STR. John Wiley and Sons Inc. 2020-07-20 2020-10 /pmc/articles/PMC7539943/ /pubmed/33021066 http://dx.doi.org/10.1111/hiv.12912 Text en © 2020 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Dravid, A
Betha, TP
Sharma, AK
Gawali, R
Mahajan, U
Kulkarni, M
Saraf, C
Kore, S
Dravid, M
Rathod, N
Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
title Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
title_full Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
title_fullStr Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
title_full_unstemmed Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
title_short Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India
title_sort efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed hiv‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in pune, india
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539943/
https://www.ncbi.nlm.nih.gov/pubmed/33021066
http://dx.doi.org/10.1111/hiv.12912
work_keys_str_mv AT dravida efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT bethatp efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT sharmaak efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT gawalir efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT mahajanu efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT kulkarnim efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT sarafc efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT kores efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT dravidm efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe
AT rathodn efficacyandsafetyofasingletabletregimencontainingtenofovirdisoproxilfumarate300mglamivudine300mgandefavirenz400mgasaswitchstrategyinvirologicallysuppressedhiv1infectedsubjectsonnonnucleosidereversetranscriptaseinhibitorcontainingfirstlineantiretroviralthe